Lanxess Sells Perlon Monofil Business to Serafin Group

Troubled German specialty chemicals producer Lanxess has sold its wholly owned subsdiary Perlon-Monofil to Germany's Serafin Group for an undisclosed sum.

The divestment had been anticipated after the company last September said it was studying "strategic options" for certain non-core businesses.

Perlon-Monofil, one of the activities Lanxess inherited in its spin-off from Bayer in 2004, is a global market leader for polyamide and polyester (PET) monofil products sold under the trade names Perlon, Atlas and Bayco.

The company with 100 employees and sales of €30 million operates a production facility and technical center at Dormagen, Germany.

Through its Nextrusion unit based near Augsburg, Germany, Serafin already has good standing within the PET monofilaments for paper machine clothing and other technical textiles, said Lanxess board member Werner Breuers.

The acquisition will strengthen the market position both of Perlon-Monofil and Nextrusion, said Serafin managing director Philipp Haindl.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.